US 11173165
Optimizing mifepristone levels for Cushing's patients
granted A61KA61K31/122A61K31/135
Quick answer
US patent 11173165 (Optimizing mifepristone levels for Cushing's patients) held by Corcept Therapeutics Incorporated expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Corcept Therapeutics Incorporated
- Grant date
- Tue Nov 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 15
- CPC classes
- A61K, A61K31/122, A61K31/135, A61K31/136, A61K31/567